Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Cisplatin
102
CHF
CHF 102.00
In stock
CDX-C0320-M250250 mgCHF 102.00
CDX-C0320-G0011 gCHF 326.00
| Product Details | |
|---|---|
| Synonyms | cis-Diammineplatinum(II) dichloride; cis-Dichlorodiammine platinum(II); cis-Platinum(II) diammine dichloride; Neoplatin; CDDP; cis-DDP; NSC119875 |
| Product Type | Chemical |
| Properties | |
| Formula |
Cl2H6N2Pt |
| MW | 300.05 |
| CAS | 15663-27-1 |
| RTECS | TP2450000 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Yellow to orange powder. |
| Solubility | Soluble in DMF (10mg/ml). Slightly soluble in water (1mg/ml). Insoluble in ethanol. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | LXZZYRPGZAFOLE-UHFFFAOYSA-L |
| Smiles | Cl[Pt]([NH3])(Cl)[NH3] |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +20°C |
| Long Term Storage | +20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at RT. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Cisplatin is an inorganic platinum complex with antineoplastic activity. Cisplatin is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin induces apoptosis and autophagy and activates ferroptosis. It is a potent chemoimmunotherapeutic drug and stimulates the immune responses by activating macrophages and other cells of the immune system. Cisplatin effects are regulated by kinases, phosphatases, and Ca2+/calmodulin.
Product References
(1) G.R. Gale, et al.; J. Natl. Cancer Inst. 51, 1227 (1973) | (2) O. Bagasra, et al.; Cancer Immunol. Immunother. 19, 142 (1985) | (3) I. Sanchez-Perez, et al.; Oncogene 16, 533 (1998) | (4) M.S. Razzaque, et al.; Histochem. Cell Biol. 111, 359 (1999) | (5) K. Seki, et al.; Cancer Chemother. Pharmacol. 45, 199 (2000) | (6) J. Lokich; Cancer Invest. 19, 756 (2001) | (7) R.N. Bose; Mini Rev. Med. Chem. 2, 103 (2002) | (8) Z.H. Siddik; Oncogene 22, 7265 (2003) | (9) R.C. Todd & S.J. Lippard; Metallomics 1, 280 (2009) | (10) H. Han, et al.; Nature Cell Biol. 24, 74 (2022)